ClinicalTrials.gg
Drug

Denosumab clinical trials

Also written Prolia, Xgeva, AMG 162 and CT-P41.

Includes 5 studies of QL1206.

studies test it
207
open now
16
in phase 3
71
first study started
2002

How each study uses Denosumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the Denosumab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
1 Jun 2010 · PROLIA · BLA 125320 (FDA, Drugs@FDA)
European Union
26 May 2010 · Prolia · EMEA/H/C/001120 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Denosumab
137
Denosumab Injection
8
Denosumab 6 month/subcutaneous
5
Denosumab (Prolia)
4
Denosumab 60 mg/ml [Prolia]
4

Brand

Prolia
67
Xgeva
40

Development codes

AMG 162
24
CT-P41
3
HLX14
2
MW031
2
CMAB807
1
INTP23
1

Biosimilars

MW032
2

Studies by the year they started

205 studies that test it; most in 2019 (22); 2 more planned to start later

Studies that test Denosumab, by start year
YearStudies
20021
20031
20046
20051
200611
20073
20082
200910
20102
20119
201211
20139
201412
201511
20169
201720
201814
201922
202012
202113
20227
20236
20247
20256

By phase

A phase 1/2 study counts in both.

Early Phase 1
5
Phase 1
30
Phase 2
66
Phase 3
71
Phase 4
40
No phase
6

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 88 · Other 119

Amgen (55) · Massachusetts General Hospital (8) · Shenzhen People's Hospital (7) · Martin Blomberg Jensen (5) · Mabwell (Shanghai) Bioscience Co., Ltd. (5) · Qilu Pharmaceutical Co., Ltd. (5) · GlaxoSmithKline (5) · Celltrion (3)

Often tested with

Tested in the same studies.

Zoledronic Acid (11) · Teriparatide (5) · Romosozumab (4) · Alendronate (4) · Pamidronate (2) · Letrozole (1) · TVB-009 (1) · Calcium (1)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Tested against it · 2 phase 3 studies under way

Denosumab is the comparator. A study of two new drugs counts under both.

  • 2Narlumosbart · RenJi Hospital, Shanghai JMT-Bio Inc. · next primary completion Jun 2028
Reaching primary completion within a year · 11, 2 in phase 3

Studies that test Denosumab, phase 3 first.

Studies

Open first, then newest update. How each study uses Denosumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 207

See all 207 studies that test Denosumab →

Given beside what is tested · 18 — Denosumab is usual care or a partner of the new treatment
As the comparator · 30 — what is tested is compared with Denosumab

Showing 20 of 30.

What changed recently

From the registry's own updates since Oct 18, 2026.

Codes

What other systems call Denosumab · ClinicalTrials.gg INT006582

  • MeSH (NLM) D000069448DenosumabConfirmed ClinicalTrials.gov, NLM, Wikidata
  • UNII (FDA) 4EQZ6YO2HIDENOSUMABConfirmed FDA, NLM, Wikidata
  • RxNorm 993449Confirmed FDA, Wikidata
  • Wikidata Q408283denosumabConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C61313DenosumabOne source FDA
  • DrugBank DB06643One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.